Moreover, our results demonstrated that acetate supplementation alleviates DNCB-induced AD-like skin damage, which is related to the presence of the FFAR2 and the Th2 (Gata3) pathways, but not to FFAR3 and GRP109a. The gene discussed is FFAR2; the disease is Alzheimer disease.